Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 811-824 , December 2006

Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation

  • Jakob R. Passweg, MD, MS (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Service d'Hématologie, Departement Medecine Interne, Hôpitaux Universitaires de Genève, Rue Micheli-du-Crest 24, 1211 Genève 14, Switzerland. Tel.: +41 61 265 45 46; Fax: +41 61 265 44 50.

References 

  1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76(12):2421–2438
  2. Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Reviews Cancer. 2002;2(11):850–861
  3. French AR, Yokoyama WM. Natural killer cells and viral infections. Current Opinion in Immunology. 2003;15(1):45–51
  4. Moretta A, Bottino C, Mingari MC, et al. What is a natural killer cell?. Nature Immunology. 2002;3(1):6–8
  5. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. The EMBO Journal. 2004;23(2):255–259
  6. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annual Review of Immunology. 2002;20:217–251
  7. Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100(6):1935–1947
  8. Borrego F, Kabat J, Kim DK, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Molecular Immunology. 2002;38(9):637–660
  9. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annual Review of Immunology. 2001;19:197–223
  10. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Reviews Immunology. 2003;3(2):108–122
  11. Lanier LL. NK cell recognition. Annual Review of Immunology. 2005;23:225–274
  12. Barao I, Murphy WJ. The immunobiology of natural killer cells and bone marrow allograft rejection. Biology of Blood and Marrow Transplantation. 2003;9(12):727–741
  13. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146–3151
  14. Robertson MJ, Soiffer RJ, Wolf SF, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. The Journal of Experimental Medicine. 1992;175(3):779–788
  15. Henslee-Downey PJ. Allogeneic transplantation across major HLA barriers. Best Practice and Research Clinical Haematology. 2001;14(4):741–754
  16. Singhal S, Henslee-Downey PJ, Powles R, et al. Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplantation. 2003;31(10):889–895
  17. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. The New England Journal of Medicine. 1998;339(17):1186–1193
  18. Martelli MF, Aversa F, Bachar-Lustig E, et al. Transplants across human leukocyte antigen barriers. Seminars in Hematology. 2002;39(1):48–56
  19. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplantation. 2001;27(8):777–783
  20. Passweg JR, Kuhne T, Gregor M, et al. Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplantation. 2000;26(10):1033–1036
  21. Rowe JM, Lazarus HM. Genetically haploidentical stem cell transplantation for acute leukemia. Bone Marrow Transplantation. 2001;27(7):669–676
  22. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333–339
  23. Eyrich M, Lang P, Lal S, et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. British Journal of Haematology. 2001;114(2):422–432
  24. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005;105(10):4135–4142
  25. Ruggeri L, Capanni M, Tosti A, et al. Innate immunity against hematological malignancies. Cytotherapy. 2002;4(4):343–346
  26. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100
  27. Ruggeri L, Capanni M, Martelli MF, et al. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Current Opinion in Hematology. 2001;8(6):355–359
  28. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–415
  29. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100(10):3825–3827
  30. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814–819
  31. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Human Immunology. 2002;63(4):271–280
  32. Hsu KC, Taylor CA, O'Reilly RJ, et al. AML Patients lacking KIR ligand for donor KIR exhibit increased overall survival in HLA-identical sibling transplants. Biology of Blood and Marrow Transplantation. 2004;10(S1, 7):
  33. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63(3):204–211
  34. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. British Journal of Haematology. 2003;123(2):323–326
  35. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103(4):1521–1526
  36. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology. 2004;172(1):644–650
  37. Triplett B, Handgretinger R, Pui CH, et al. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood. 2006;107(3):1238–1239
  38. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462–2465
  39. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95(1):67–71
  40. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 2002;100(2):397–405
  41. Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation. 2002;8(11):625–632
  42. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplantation. 2003;31(1):39–44
  43. Naliboff BD, Benton D, Solomon GF, et al. Immunological changes in young and old adults during brief laboratory stress. Psychosomatic Medicine. 1991;53(2):121–132
  44. Schedlowski M, Falk A, Rohne A, et al. Catecholamines induce alterations of distribution and activity of human natural killer (NK) cells. Journal of Clinical Immunology. 1993;13(5):344–351
  45. Lassailly F, Sielleur I, Blaise D, et al. rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells. Bone Marrow Transplantation. 2005;35(1):25–32
  46. Tayebi H, Kuttler F, Saas P, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Experimental Hematology. 2001;29(4):458–470
  47. Wolf CE, Meyer M, Riggert J. Leukapheresis for the extraction of monocytes and various lymphocyte subpopulations from peripheral blood: product quality and prediction of the yield using different harvest procedures. Vox Sanguinis. 2005;88(4):249–255
  48. Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells, Molecules and diseases. 2004;33(3):261–266
  49. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18(11):1835–1838
  50. Iyengar R, Handgretinger R, Babarin-Dorner A, et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy. 2003;5(6):479–484
  51. Koehl U, Esser R, Zimmermann S, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klinische Padiatrie. 2005;217(6):345–350
  52. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004;6(1):15–22
  53. Luhm J, Brand JM, Koritke P, et al. Large-scale generation of natural killer lymphocytes for clinical application. Journal of hematotherapy and stem cell research. 2002;11(4):651–657
  54. Gentilini C, Hilbers U, Hartung G, et al. Early transfer of highly purified alloreactive CD56+CD3– NK-cells after haploidentical stem cell transplantation: promising results of a phase I study. Bone Marrow Transplantation. 2006;37(S1):S35
  55. Slavin S, Morecki S, Shapira M, et al. Immunotherapy using rIL-2 activated mismatched donor lymphocytes positively selected for CD56+ for the treatment of resistant haematologic malignancies after stem cell transplantation. Bone Marrow Transplantation. 2004;33(S174):
  56. Koehl U, Sörensen J, Esser R, et al. Immunotherapy with highly purified CD56+CD3– natural killer cells for paediatric patients after haploidentical stem cell transplantation. Bone Marrow Transplantation. 2006;37(S1):S35
  57. Bethge WA, Faul C, Bornhäuser M, et al. Haploidentical allogeneic haematopoietic cell transplantation in adults with CD3/CD19 depleted grafts and reduced-intensity conditioning: fast engraftment and low toxicity. Bone Marrow Transplantation. 2006;37(S1):S33
  58. Bethge WA, Haegele M, Faul C, et al. CD3/CD19 depleted as compared to CD34 selected grafts allow haploidentical allogeneic haematopoietic cell transplantation with faster engraftment and immune reconstitution. Bone Marrow Transplantation. 2006;37(S1):S33
  59. Igarashi T, Wynberg J, Srinivasan R, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104(1):170–177
  60. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–3057
  61. Uharek L, Zeis M, Glass B, et al. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia. 1996;10(11):1758–1764
  62. Nagao F, Suzui M, Takeda K, et al. Mobilization of NK cells by exercise: downmodulation of adhesion molecules on NK cells by catecholamines. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2000;279(4):R1251–R1256
  63. Nowbakht P, Ionescu MC, Rohner A, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood. 2005;105(9):3615–3622
  64. Siegler U, Kalberer CP, Nowbakht P, et al. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia. 2005;19(12):2215–2222
  65. Langenkamp U, Rohner A, Siegler U, et al. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of AML cells to NK cell-mediated lysis. Bone Marrow Transplantation. 2006;37(S1):S23

PII: S1521-6926(06)00041-7

doi: 10.1016/j.beha.2006.06.004

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 811-824 , December 2006

Article Tools

* Image Usage & Resolution